The Benefit of CDK4/6 Inhibitors Applies Equally to Older Women with Breast Cancer

TON Web Exclusives - Breast Cancer

To date, 3 CDK4/6 inhibitors have been approved by the FDA for the treatment of patients with breast cancer: palbociclib (Ibrance), ribociclib (Kisqali), and abemaciclib (Verzenio). These agents work by blocking the function of proteins CDK4 and CDK6, both which drive cell multiplication, thereby fueling tumor growth.

Treatment with CDK4/6 inhibitors appears to have the same efficacy in older patients with breast cancer, compared with younger ones, according to new findings presented at the 2017 San Antonio Breast Cancer Symposium.

“As we approve new drugs to treat cancer, it is important to try to improve our understanding of the efficacy and safety of these drugs in our older patients,” said the study’s lead investigator, Harpreet Singh, MD, Medical Officer, Scientific Liaison, Cancer in Older Adults, Office of Hematology and Oncology Products, FDA. “Older patients traditionally have been underrepresented in oncology clinical trials, so pooling outcomes of older patients across clinical trials in the same drug class allows us to gain insight into how these patients may benefit.”

To determine the efficacy and safety of CDK4/6 inhibitors in an older population, Dr Singh and colleagues pooled and analyzed data from randomized controlled trials that evaluated the 3 FDA-approved CDK4/6 inhibitors in combination with an aromatase inhibitor, as the first-line treatment for postmenopausal women with hormone receptor–positive metastatic breast cancer. The cohort included 1334 patients (intention-to-treat population, 1992), of whom 42% were aged ≥65 years, and 24% were ≥70 years.

The primary end point of the study was progression-free survival (PFS) in patients aged ≥70 years, and in control groups.

In patients aged ≥70 years who were treated with a CDK4/6 inhibitor in combination with an aromatase inhibitor, the estimated PFS was not reached, compared with an estimated PFS of 16.8 months for those treated only with an aromatase inhibitor.

In patients aged <70 years who were treated with a CDK4/6 inhibitor, the estimated PFS was 23.8 months, compared with an estimated 13.8 months for those treated only with an aromatase inhibitor.

The researchers also evaluated safety in 1106 patients who received ≥1 doses of a CDK4/6 inhibitor.

Older patients were more likely than the younger patients to discontinue treatment because of side effects. Twenty percent of the patients aged <70 years discontinued treatment, compared with 17% of patients aged ≥65 years and 8% of those aged <65 years. The most common events that led to discontinuation of treatment across all age- groups were infection, fatigue, blood count abnormalities (neutropenia), liver enzyme abnormalities, and diarrhea.

“Our findings suggest that there is no treatment difference across age subgroups in terms of efficacy of CDK4/6 inhibitors,” Dr Singh said. “This is an important piece of information as health care providers and patients weigh their treatment options as new therapies are approved.”

A co-investigator on the study, Lynn Howie, MD, a medical officer in the FDA Center for Drug Evaluation and Research, Office of Hematology and Oncology Products, added that the potential benefit of a CDK4/6 inhibitor for older patients with breast cancer should be weighed against the increased risk for toxicity. In addition to the higher rates of discontinuation of treatment, older patients often required more dose modifications to help them manage side effects.

Source:

Singh H, Howie LJ, Bloomquist E, et al. A U.S. Food and Drug Administration pooled analysis of outcomes of older women with hormone-receptor positive metastatic breast cancer treated with a CDK4/6 inhibitor as initial endocrine based therapy. Presented at: 2017 San Antonio Breast Cancer Symposium; December 5-9, 2017. Abstract GS5-06.

Related Items
Kisqali (Ribociclib): Second CDK4/CDK6 Inhibitor Approved for Postmenopausal Women with HR-Positive, HER2-Negative Advanced Breast Cancer
Lisa A. Raedler, PhD, RPh, Medical Writer
2018 Third Annual Oncology Guide to New FDA Approvals published on May 9, 2018 in FDA Approvals, News & Updates, Breast Cancer
Verzenio (Abemaciclib) a New CDK4/CDK6 Inhibitor Approved for HR-Positive, HER2-Negative Advanced or Metastatic Breast Cancer
Loretta Fala, Medical Writer
2018 Third Annual Oncology Guide to New FDA Approvals published on May 9, 2018 in FDA Approvals, News & Updates, Breast Cancer
Immunotherapy Combination Shows Promising Results in HER2 1+/2+ Breast Cancer
TOP - May 2018, Vol 11, No 1 published on May 1, 2018 in Adverse Effects, Breast Cancer
Breaking News: Sellas Announces Promising Data on NeuVax in Combination with Herceptin in HER2 1+/2+ Breast Cancer
TOP Web Exclusives published on April 7, 2018 in Breast Cancer, Online Only
Taselisib, a PI3K Inhibitor, Shrinks Tumors in Early Breast Cancer, with Added Activity in Patients with PI3KCA Mutation
TON - March 2018, Vol 11, No 1 published on March 9, 2018 in Breast Cancer, Drug Updates & News, ESMO
Blood-Based Biopsy Can Predict Breast Cancer Recurrence
TON Web Exclusives published on February 26, 2018 in Breast Cancer
Immunotherapy Continues to Gain Momentum in Breast Cancer
JHOP - December 2017 Vol 7, No 4 published on February 26, 2018 in Breast Cancer
Arm Morbidity Higher with Extensive Lymph Node Surgery in Younger Patients with Breast Cancer
JHOP - December 2017 Vol 7, No 4 published on February 26, 2018 in Breast Cancer
Dose-Intense Chemotherapy Shown to Improve Outcomes in Patients with Breast Cancer
JHOP - December 2017 Vol 7, No 4 published on February 26, 2018 in Breast Cancer
Long-Term Data from the TEAM Trial Support Individualized Adjuvant Endocrine Therapy Strategy for Postmenopausal Women with HR-Positive Early Breast Cancer
TON Web Exclusives published on December 28, 2017 in Breast Cancer
Last modified: May 11, 2018